Godavari Drugs
- Market cap
- ₹ 122 Cr.
- P/E
- 34x
- P/B
- 1.66x
- 52-week range
- 69.7 – 144.35
- ROE
- 6%
- ROCE
- 7%
- Dividend yield
- 0%
- Debt / equity
- 1.08
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Godavari Drugs Limited is an India-based company, which is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and its intermediates. The Company is engaged in the business of contract manufacturing, loan license manufacturing, manufacturing and supply of API, drug intermediaries and fine chemicals. It operates through manufacture and sale of API and its intermediates segment. Its manufacturing facilities are located at the Maharashtra Industrial Development Corporation estate at Nanded, Maharashtra, India. The Company's facility has multiple production blocks for API's, drug intermediates and fine chemicals.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Godavari Drugs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)34 against a typical 34.3: cheaper than most peers (1st = cheapest).110th of 220
- Sales growth+17.4% against a typical +15.6% from a year earlier.90th of 197
- Profit growth+6.7% against a typical +18.9% from a year earlier.98th of 160
- Share price, 3 months+11% against a typical −0.5%.59th of 200
- Size₹ 122 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).142nd of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 43 | 39 | 32 | 26 | 30 | 26 | 24 | 27 | 22 | 33 | 28 |
| Expenses | 36 | 40 | 34 | 29 | 23 | 27 | 22 | 21 | 25 | 20 | 30 | 25 |
| Operating Profit | 3 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 |
| OPM % | 7.8% | 8.2% | 11.6% | 10% | 11.1% | 8.7% | 12.2% | 12.2% | 7.5% | 11.1% | 8.9% | 9% |
| Other Income | 0 | −0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Tax % | 32.8% | 29.9% | 4.7% | 18.9% | 12.8% | 16.1% | 38.2% | 19.9% | 10.6% | 25.5% | 20.4% | 5.9% |
| Net Profit | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS in Rs | 1.14 | 1.62 | 3.53 | 2.16 | 1.45 | 1.02 | 1.18 | 1.38 | 1.33 | 1.01 | 1.27 | 1.1 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 4%
- 5 Years
- −3%
- 3 Years
- −13%
- TTM
- 5%
- 10 Years
- 11%
- 5 Years
- −2%
- 3 Years
- 2%
- TTM
- 3%
- 10 Years
- 10%
- 5 Years
- 8%
- 3 Years
- 1%
- TTM
- —
- 10 Years
- 11%
- 5 Years
- 12%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Godavari Drugs | ₹ 121.00 | ₹ 122 Cr. | 34x | 1.7x | 6% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.9x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 74x | 11.6x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 76.4x | 20.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28x | 3.4x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.3x | 4.3x | 19.7% | 18.5% |
Management
- Mukund Kakani
- Managing Director, Executive Director
- Mohit Jaju
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.